Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Centaurus Biopharma Co., Ltd.

Lianyungang Runzhong Pharmaceutical Co., Ltd.

Medshine Discovery Inc.

Other

Jiangsu Chiatai Tianqing Pharmaceutical Co., Ltd.

Shouyao Holdings (beijing) Co., Ltd.

Shanghai Dude Medical Science and Technology Co., Ltd.

Advenchen Laboratories Nanjing Ltd

Lainyungang Runzhong Pharmaceutical Co., Ltd.

Chia Tai Tianqing Pharmaceutical Group Go., Ltd.

Nanjing Shunxin Pharmaceutical Co., Ltd.

Nanjing Shunxin Pharmaceuticals Co., Ltd. of Chiatai Tianqing Pharmaceutical Group

Xiquan Zhang

Aiming Zhang

Hongjiang Xu

Xin Tian

Ling Yang

Fei Liu

Shanchun Wang

Rui Zhao

Xunqiang Wang

Shuhui Chen

Charles Z Ding

Yongxin Han

Wei Song

Xijie Liu

Kevin X Chen

Ying Zhang

Dengming Xiao

Jian Li

Hui Zhang

Wei Huang

Chengde Wu

Hong Luo

Yuandong Hu

Ping Dong

Zhao Wang

Kai Zhou

Xin Liu

Jie Xu

Hongmei Gu

Yanlong Liu

Chunguang Xia

Zhou Zhou

Xiangjian Wang

Xinlu Li

Song Tang

Huadong Yao

Weiwei Feng

Yong Peng

Na Zhao

Jian Xiong

Cheng Xie

Chunli Shen

Lin Liu

Xiongbin Xu

Wei Shi

Yizhong Zhu

Xiaobing Yan

Shulong Wang

Xinhe Xu

Hao Yu

Xingdong Cheng

Hai Jiang

Shenglin Chen

Feng Gong

Jie Dai

Xiaopeng Guo

Leilei Yang

Xiaole Zhan

Wenwei Xu

Guangming Sang

Fei Sun

Guoping Hu

Lihong Hu

Dan Li

Baiyong Li

Zhongmin Maxwell Wang

Yu Xia

Weidong Li

Rong Li

Gang Wu

Zhen Gong

Xueyan Zhu

Zhaobing Xu

Wei Zhao

Lifang Wu

Boyu Hu

Linghui Wu

Hubo Wang

Yanxin Yu

Zhilin Chen

Yingchun Liu

Zongbin Li

Xingfeng Ge

Zheng Liu

Dandan Lu

Ping Xu

Lulu Wang

Xiaoping Chen

Xiongxiong He

Xi Han

Zhongnan Xu

Wenjun Geng

Hongying Zhang

Jianqiu Tang

Rui Kong

Shan Chen

Peng Lv

Jinhua Du

The present invention relates to use of a pyrrolopyrimidine compound for treating hemophagocytic syndrome, and particularly relates to use of a compound of formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition thereof for treating hemophagocytic syndrome.

Use of pyrrolopyrimidine compound for treating hemophagocytic syndrome

The present application relates to the field of biomedicine, and relates to a combined pharmaceutical composition for treating biliary tract tumor, liver cancer, triple negative breast cancer or lung cancer. The combined pharmaceutical composition comprises an anti-PD-L1 antibody and anlotinib, and has good anti-biliary tract tumor, liver cancer, triple negative breast cancer or lung cancer activity.

Combined pharmaceutical composition for treating tumor

The present application provides a therapeutic combination of a quinoline derivative and an antibody, which comprises an immune checkpoint inhibitor and a tyrosine kinase inhibitor, wherein the tyrosine kinase inhibitor is a compound of formula I or a pharmaceutically acceptable salt thereof. The therapeutic combination in the present application shows good activity against lung tumor and liver tumor.

Therapeutic combination of quinoline derivative and antibody

Disclosed is a trifluoromethyl-substituted sulfonamide BCL-2-selective inhibitor, in particular disclosed are a compound of formula I, a stereoisomer or a pharmaceutically acceptable salt thereof, a preparation method therefor, and a pharmaceutical composition thereof. Also disclosed are the uses of said compound and of a pharmaceutical composition comprising same for treating anti-apoptotic BCL-2-related diseases, such as cancer.

Trifluoromethyl-substituted sulfonamide as BCL-2-selective inhibitor

The present application relates to the field of medicine, and relates to crystals of quinoline derivatives, and in particular, to crystals of a quinoline derivative anhydride and a solvate, as well as a method for preparing the crystals, pharmaceutical compositions containing the crystals, and a use thereof in the field of medicine. The present application further provides a preparation method therefor, which has a high yield, has mild crystallization conditions, is suitable for industrial production, and may better meet the needs of the pharmaceutical industry.

Crystals of quinolone derivatives

A drug combination containing a TLR7 agonist. Specifically, a drug combination jointly using the compound of formula I acting as a TLR7 agonist and entecavir for the treatment of hepatitis B virus infection and a use thereof, the drug combination having a good anti-hepatitis B virus infection effect.

Drug combination containing TLR7 agonist

Disclosed is a methyl- and trifluoromethyl-containing disubstituted sulfonamide selective BCL-2 inhibitor; specifically disclosed are a compound of formula I, a stereoisomer or pharmaceutically acceptable salt of same, a preparation method therefor, and a pharmaceutical composition comprising the compound. Also disclosed are uses of the compound and of the pharmaceutical composition comprising the compound in treating anti-apoptotic protein BCL-2-related diseases such as cancer.

Methyl- and trifluoromethyl-containing disubstituted sulfonamide selective BCL-2 inhibitor

Disclosed are a compound of formula I as a toll-like receptor 7 (TLR7) agonist or a pharmaceutically acceptable salt thereof for treating colorectal cancer, a pharmaceutical combination for treating colorectal cancer comprising the TLR7 agonist and a tyrosine kinase inhibitor, and the use of the compound of formula I or the pharmaceutically acceptable salt thereof and the pharmaceutical combination for treating colorectal cancer.

TLR7 agonist for treating colorectal cancer and pharmaceutical combination thereof

The invention is in the field of antibody formulations, and particularly relates to a pharmaceutical composition of a humanized monoclonal anti-PD-L1 antibody, wherein the pharmaceutical composition comprises 1-150 mg/ml of the humanized monoclonal anti-PD-L1 antibody, a buffer at 3-50 mM, 2-150 mg/ml of an isotonic adjuster/stabilizer and 0.01-0.8 mg/ml of a surfactant, and has a pH of about 4.5-6.8. The formulations prevent antibody aggregates therein from increasing, while enabling better maintenance of the biological binding activity of the antibody for a long time.

Pharmaceutical composition of humanized monoclonal anti-PD-L1 antibody

The present application relates to a compound of formula I as a toll-Like receptor 7 (TLR7) agonist or a pharmaceutically acceptable salt thereof for treating lung cancer, a pharmaceutical combination of the TLR7 agonist and a tyrosine kinase inhibitor for treating lung cancer, and the use of the compound of formula I or the pharmaceutically acceptable salt thereof and the pharmaceutical combination for treating lung cancer.

TLR7 agonist and pharmaceutical combination thereof for treating lung cancer

The present application belongs to the field of medicine. In particular, the present application relates to a diarylthiohydantoin compound as an androgen receptor antagonist or a pharmaceutically acceptable salt thereof, a preparation method of the same, a pharmaceutical composition comprising the compound, and a use thereof in treating a cell proliferative disease mediated by androgen. The compound of the present application has good antagonistic effect on androgen receptor and exhibits excellent antitumor effect.

Diarylthiohydantoin compound as androgen receptor antagonist

The present application relates to a method for preparing trifluridine, comprising reacting a compound of formula III with a compound of formula IV in a first solvent in the presence of an acid to obtain a compound of formula II, and performing further reaction to obtain trifluridine.

Method for preparing trifluridine

Disclosed are a class of anti-HBV tetrahydroisoxazolo[4,3-c]pyridine compounds and pharmaceutically acceptable salts thereof or isomers thereof, the compounds being represented by the formula (I). 

Anti-HBVtetrahydroisoxazolo[4,3-c]pyridine compounds

The present invention provides a quinoline derivative for treating triple-negative breast cancer and use thereof in preparing a pharmaceutical composition for treating a tumor. Specifically, the present invention relates to use of quinoline derivative 1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yl)oxy-6-methoxyquinoline-7-yl]oxy]methyl]cyclopropylamine in the treatment of triple-negative breast cancer, 

Quinoline derivative for treatment of triple-negative breast cancer

The present invention belongs to the field of medicine, relates to an inhaled preparation of isoglycyrrhizic acid or a salt thereof, and in particular relates to an inhaled preparation of magnesium isoglycyrrhizinate and the use thereof in preparing drugs for treating respiratory system diseases.

Inhaled preparation of isoglycyrrhizic acid or salt thereof, and use in preparing drugs for treating respiratory system diseases

Growing community of inventors

Lianyungang, China

Xiquan Zhang